Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Jay Lowe who wrote (179)	5/13/1998 6:14:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 586

If we can get CYPB to candidly discuss the Prosorba Technology and future plans then we'd have something. Like I said, I am willing to talk to anyone. As an investor, I would like to feel confident about the technology and the management. As a physician, I am simply curious how this works and whether other patients with auto-immune disorders could benefit. I just went over some financials with my brother-in-law. He said that there are 38 million CYPB shares outstanding (a lot). The Price/Book ration is high at 22.36. That means that there is a lot of confidence in the company. However, they only have 8 million in assets. Which means that if something goes wrong.....we are looking at a penny stock. These numbers are from the WSJ website briefing books. I am no financial wizard. If there is someone who could shed some further light onto the CYPB financial picture I would greatly appreciate it.